Pathogenesis
|
*Pathogenesis of PPI induced- HSRs especially after 3-24 hours, as well
as co-factors’ impact on the type and severity of reactions (fasting,
food intake, infection, simultaneously intake of NSAID), route of
administration, dose, type of coating and metabolism.
*Role of IgE in PPI induced immediate HSRs
|
Immediate type HSRs |
Immediate type
HSRs |
Skin tests
|
*The factors related to skin test positivity
*Larger scale multicenter studies to confirm optimal test concentrations
*Unified algorithm for testing with culprit and alternative PPIs
|
DPT
|
*Larger scale multicenter studies to confirm optimal test doses and
provide the risk stratification
*The exact degree of cross-reactivity between different PPIs
|
In vitro tests
|
*Determination of specific IgE antibodies to PPIs
*The role of BAT in the diagnosis of HSRs to PPIs
|
Management
|
*Drug antigenic determinants responsible for cross-reactivity
*More data regarding desensitization to PPIs
*The role of risk factors and co-factors in the type of reaction as in
cross-reactivity determination
|
Delayed type HSRs |
Delayed type HSRs |
Skin tests
|
* Role of patch tests and delayed readings of IDTs in diagnosis
* Optimal concentrations and vehicles for patch tests, method of skin
testing protocol
* To study cross-reactivity profiles
|
DPT |
* The role of DPT in the diagnosis |
In vitro tests |
* The roles of LTT and LAT in the
diagnosis |
Management |
* More data about PPI-induced delayed
HSRs |